our Premium Content: News alerts, weekly reports and conference planners

GENE:

PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

News alerts, weekly reports and conference planners

NAVIG-1: New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study (clinicaltrials.gov)

P1/2, N=35, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: May 2027 --> Mar 2028 | Trial primary completion date: May 2027 --> Mar 2028

3 days ago

Trial completion date • Trial primary completion date

MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

MGMT promoter methylation

Midkine (MDK) as a Central Regulator of the Tumor Microenvironment: From Developmental Cytokine to Therapeutic Target. (PubMed, Cancer Lett)

Finally, we review translational opportunities and challenges, including candidate biomarkers (tumor MDK by IHC/RNA and circulating MDK by ELISA) and rational combination strategies that pair MDK blockade with MAPK-pathway inhibitors or PD-1/PD-L1 immunotherapy. Collectively, these data position MDK as a tractable node connecting tumor-intrinsic signaling with stromal and immune regulation.

1 month ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8) • NCL (Nucleolin) • LRP1 (LDL Receptor Related Protein 1) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

Human organoid tumor transplantation identifies functional glioblastoma-microenvironment communication mediated by PTPRZ1. (PubMed, Cell Rep)

We observe that knocking down nTME PTPRZ1, a receptor tyrosine phosphatase implicated in cancer cell migration, results in an increased fraction of mesenchymal cells, enrichment of epithelial-to-mesenchymal gene programs, and an elevated tumor microtube length in co-cultured primary patient tumors. This phenotype is not mediated by PTPRZ1's catalytic activity, suggesting a mechanism of tumor cell fate driven by nTME PTPRZ1, highlighting the strengths of the HOTT system.

1 month ago

Journal

PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

Midkine as a therapeutic node in NF1-driven neuro‑oncology: Biology, biomarkers, and translational strategies. (PubMed, Biomed Pharmacother)

We propose combining MDK blockade with MEK, SHP2, or immune checkpoint inhibitors, using serum MDK and phospho-signaling as pharmacodynamic markers. We emphasize the near‑term opportunity in NF1‑OPG and MPNST while drawing lessons from NF1‑altered tumors outside the nervous system that reinforce combination strategies for neuro‑oncology.

1 month ago

Review • Journal • IO biomarker

ALK (Anaplastic lymphoma kinase) • NF1 (Neurofibromin 1) • LRP1 (LDL Receptor Related Protein 1) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

2ms

Single-cell and spatial transcriptome sequencing analysis reveals characteristics of a unique subpopulation in high-grade IDH-mutant astrocytoma. (PubMed, Cell Oncol (Dordr))

Our single-cell RNA sequencing analysis identifies a distinct tumor cell subpopulation present in high-grade (WHO grade 3-4) adult IDH-mutant astrocytoma. This cluster, which likely arises from malignant progression in adult astrocytoma, may provide new insights for developing therapeutic strategies against this clinically challenging disease.

2 months ago

Journal

PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

IDH wild-type

3ms

Comprehensive Molecular Diagnostic Tests in Non-Small Cell Lung Cancer: Frequency of ALK, ROS1, RET, and Other Gene Fusions/Rearrangements in a Romanian Cohort. (PubMed, Cancers (Basel))

These alterations were mutually exclusive with common drivers such as EGFR or KRAS. Detection of rare fusions highlights the therapeutic potential of comprehensive NGS profiling in Romanian NSCLC patients.

3 months ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD74 (CD74 Molecule) • TACC3 (Transforming acidic coiled-coil containing protein 3) • ETV6 (ETS Variant Transcription Factor 6) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

EGFR mutation • EGFR L858R • ALK positive • RET fusion • ALK fusion • ROS1 fusion

Oncomine Focus Assay

3ms

Analysis of PTPRZ expression in glioma and schwannoma - PTPRZ-long is highly expressed and shed in glioma. (PubMed, Biochem Biophys Res Commun)

Applying a newly established sandwich ELISA designed to detect the long isoform-derived soluble PTPRZ (sPTPRZ-long), together with immunoblotting using multiple antibodies, we verified the absence of sPTPRZ-long in schwannoma CSF samples. These findings emphasize that PTPRZ-long expression and shedding into CSF are glioma-specific events, supporting its potential use as a molecular biomarker for glioma diagnosis.

3 months ago

Journal

PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

6ms

Enhancer Reprogramming Reveals the Tumorigenic Role of PTPRZ1 in Lung Squamous Cell Carcinoma. (PubMed, Adv Sci (Weinh))

This work illustrates enhancer addiction as a hallmark of LUSC, identifies the PTPRZ1-MDK axis as an important targetable pathway, and establishes a paradigm for dissecting epigenetic vulnerabilities in solid tumors through multi-omics integration. These findings advance precision oncology strategies for LUSC, bridging epigenomic dysregulation to therapeutic intervention.

6 months ago

Journal

SOX2 • TP63 (Tumor protein 63) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

6ms

Deep learning-based feature discovery for decoding phenotypic plasticity in pediatric high-grade gliomas single-cell transcriptomics. (PubMed, Comput Biol Med)

By addressing underlying patterning processes and plasticity networks as therapeutic vulnerabilities, our findings provide precision medicine strategies aimed at modulating glioma cell fates and overcoming therapeutic resistance. We suggest transition therapy toward neuronal-like lineage differentiation as a potential precision therapy to help stabilize pHGG plasticity and aggressivity.

6 months ago

Journal

NOTCH2 (Notch 2) • IGF2 (Insulin-like growth factor 2) • MEIS1 (Meis Homeobox 1) • CXXC5 (CXXC Finger Protein 5) • GATA1 (GATA Binding Protein 1) • ANXA6 (Annexin A6) • DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • H3-3A (H3.3 Histone A) • GFAP (Glial Fibrillary Acidic Protein) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

IDH wild-type

6ms

Transcriptomic HEPN1 signatures predict treatment response in low grade glioma. (PubMed, Discov Oncol)

The system elucidates the mechanism of iron death related genes in glioma heterogeneity, providing an important theoretical basis for precise treatment of gliomas.

6 months ago

Journal

SOX2 • OLIG2 (Oligodendrocyte Transcription Factor 2) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

7ms

Astrocyte-derived PTPRZ1 regulates astrocyte morphology and excitatory synaptogenesis. (PubMed, bioRxiv)

Moreover, altered PTPRZ1 expression is associated with schizophrenia and glioblastoma. Therefore, this mouse model is a valuable resource for investigating cell-type-specific PTPRZ1 function in numerous neurodevelopmental and neuropathological mechanisms.

7 months ago

Journal

PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)

8ms

Defining the extracellular matrix for targeted immunotherapy in adult and pediatric brain cancer. (PubMed, NPJ Precis Oncol)

We validate ECM-targeted CAR T cell therapy, including Glypican-2 (GPC2), which shows strong efficacy against pediatric DIPG. These findings highlight ECM-focused immunotherapy as a promising strategy to overcome HGGs' immunosuppressive TME, particularly in pediatric patients.

8 months ago

Journal

SDC1 (Syndecan 1) • CSPG4 (Chondroitin Sulfate Proteoglycan 4) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)